{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:51:32Z","timestamp":1761630692219},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1097\/pai.0000000000000013","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T17:01:46Z","timestamp":1406048506000},"page":"648-651","source":"Crossref","is-referenced-by-count":15,"title":["BRAF Mutations in Metastatic Malignant Melanoma"],"prefix":"10.1097","volume":"22","author":[{"given":"Laleh","family":"Ehsani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin E.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momin T.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-3-20210126","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00403-012-1223-7","article-title":"Upcoming strategies for the treatment of metastatic melanoma.","volume":"304","author":"Spagnolo","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"R3-3-20210126","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.sder.2010.10.005","article-title":"Epidemiology of melanoma.","volume":"29","author":"Rigel","year":"2010","journal-title":"Semin Cutaneous Med Surg"},{"key":"R5-3-20210126","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":". Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-3-20210126","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":". A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R7-3-20210126","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11640870-000000000-00000","article-title":". Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.","volume":"72","author":"Sharma","year":"2012","journal-title":"Drugs"},{"key":"R8-3-20210126","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":". High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"R9-3-20210126","first-page":"165","article-title":"DTIC (NSC-45388) in malignant melanoma: a perspective.","volume":"60","author":"Comis","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"R10-3-20210126","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.1995.13.12.2895","article-title":". Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.","volume":"13","author":"Bedikian","year":"1995","journal-title":"J Clin Oncol"},{"key":"R11-3-20210126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":". Roles of the RAFMEKERK and PI3KPTENAKT pathways in malignant transformation and drug resistance.","volume":"46","author":"McCubrey","year":"2006","journal-title":"Adv Enzyme Regul"},{"key":"R12-3-20210126","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":". Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R13-3-20210126","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bcp.2010.03.019","article-title":"BRAF as therapeutic target in melanoma.","volume":"80","author":"Wellbrock","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"R16-3-20210126","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.sder.2012.07.007","article-title":". Molecular platforms utilized to detect BRAF V600E mutation in melanoma.","volume":"31","author":"Curry","year":"2012","journal-title":"Semin Cutan Med Surg"},{"key":"R17-3-20210126","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nrm1498","article-title":"The RAF proteins take centre stage.","volume":"5","author":"Wellbrock","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R18-3-20210126","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/carcin\/bgp337","article-title":"Targets of Raf in tumorigenesis.","volume":"31","author":"Niault","year":"2010","journal-title":"Carcinogenesis"},{"key":"R19-3-20210126","doi-asserted-by":"crossref","first-page":"9719","DOI":"10.1158\/0008-5472.CAN-05-1683","article-title":". Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.","volume":"65","author":"Emuss","year":"2005","journal-title":"Cancer Res"},{"key":"R20-3-20210126","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1128\/MCB.15.11.6430","article-title":". Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3 T3 cells.","volume":"15","author":"Pritchard","year":"1995","journal-title":"Mol Cell Biol"},{"key":"R21-3-20210126","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":". Distinct sets of genetic alterations in melanoma.","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"R22-3-20210126","first-page":"197","article-title":"Treatment of cutaneous melanoma: current approaches and future prospects.","volume":"2","author":"Algazi","year":"2010","journal-title":"Cancer Manag Res"},{"key":"R23-3-20210126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":". Oncogenic BRAF induces melanoma cell invasion by down regulating the cGMP-specific phosphodiesterase PDE5A.","volume":"19","author":"Arozarena","year":"2011","journal-title":"Cancer Cell"},{"key":"R24-3-20210126","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2006.06.0442","article-title":". Toward a molecular classification of melanoma.","volume":"25","author":"Fecher","year":"2007","journal-title":"J Clin Oncol"},{"key":"R25-3-20210126","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":". BRAFV600E cooperates with Pten silencing to elicit metastatic melanoma.","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat Genet"},{"key":"R27-3-20210126","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":". Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.","volume":"37","author":"Long","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R28-3-20210126","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":". Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"R29-3-20210126","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":". Immunohistochemical testing of BRAF V600E status in 1120 tumor tissue samples of patients with brain metastases.","volume":"123","author":"Capper","year":"2012","journal-title":"Acta Neuropathol"}],"container-title":["Applied Immunohistochemistry & Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAI.0000000000000013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:29:51Z","timestamp":1620966591000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00129039-201410000-00003"}},"subtitle":["Comparison of Molecular Analysis and Immunohistochemical Expression"],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/pai.0000000000000013","relation":{},"ISSN":["1541-2016"],"issn-type":[{"value":"1541-2016","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}